Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FWYLZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Zanidatamab zovodotin
|
|||||
| Synonyms |
ZW 49; ZW-49; ZW49; anti-HER2 x HER2 ADC
Click to Show/Hide
|
|||||
| Organization |
Zymeworks BC, Inc.; BeiGene Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 4 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 1
Esophageal cancer [ICD11:2B70]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
HER2(+) solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Zanidatamab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
ZD02044
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-PEG3-Val-Cit
|
Linker Info | ||||
| Combination Type |
Zovodotin (ZD001-02044)
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.